Intervention not reported
the toxic and side effects of leukopenia after chemotherapy(no special data in trial of Zhang 2006) · patients with induction of remission in advanced or late gastric cancer
It is very uncertain whether the intervention changes the toxic and side effects of leukopenia after chemotherapy(no… (very low certainty).
1 finding from 1 review
Intervention not reported
the toxic and side effects in digestive system after chemotherapy · patients with induction of remission in advanced or late gastric cancer
It is very uncertain whether the intervention changes the toxic and side effects in digestive system after chemotherapy (very low certainty).
1 finding from 1 review
Intervention not reported
the toxic and side effects of leukopenia after chemotherapy(no special data in trial of Jia 2003, Zhang 2009) · patients with induction of remission in advanced or late gastric cancer
It is very uncertain whether the intervention changes the toxic and side effects of leukopenia after chemotherapy(no… (very low certainty).
1 finding from 1 review
Intervention not reported
the toxic and side effects in digestive system after chemotherapy(no special data in trial of Fu 2011, Liu 2009a, Zhang 2010) · patients with induction of remission in advanced or late gastric cancer
It is very uncertain whether the intervention changes the toxic and side effects in digestive system after chemotherapy(no… (very low certainty).
1 finding from 1 review
Intervention not reported
the toxic and side effects of leukopenia after chemotherapy · patients with induction of remission in advanced or late gastric cancer
It is very uncertain whether the intervention changes the toxic and side effects of leukopenia after chemotherapy (very low certainty).
1 finding from 1 review
Clinical relapse · Participants with Crohn's disease in remission
Usual care may leads to lower relapse at 12, 18 or 24 months compared with immunosuppressive withdrawal after monotherapy (low certainty).
1 finding from 1 review
New CD‐related complications · Participants with Crohn's disease in remission
It is very uncertain whether usual care changes new CD‐related complications compared with immunosuppressive withdrawal after monotherapy (very low certainty).
1 finding from 1 review
Adverse events · Participants with Crohn's disease in remission
Usual care showed no clear difference in adverse events compared with immunosuppressive withdrawal after monotherapy (low certainty).
1 finding from 1 review
Serious adverse events · Participants with Crohn's disease in remission
It is very uncertain whether usual care changes serious adverse events compared with immunosuppressive withdrawal after monotherapy (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Participants with Crohn's disease in remission
It is very uncertain whether usual care changes withdrawal due to adverse events compared with immunosuppressive withdrawal after monotherapy (very low certainty).
1 finding from 1 review
Relapse · Participants with Crohn's disease in remission
Usual care showed no clear difference in relapse at 12 or 24 months compared with immunosuppressive withdrawal after combination therapy (low certainty).
1 finding from 1 review
Adverse events · Participants with Crohn's disease in remission
Usual care showed no clear difference in adverse events compared with immunosuppressive withdrawal after combination therapy (low certainty).
1 finding from 1 review
Serious adverse events · Participants with Crohn's disease in remission
It is very uncertain whether usual care changes serious adverse events compared with immunosuppressive withdrawal after combination therapy (very low certainty).
1 finding from 1 review
Overall survival · people with advanced gastric cancer
Combination probably leads to lower overall survival compared with single‐agent chemotherapy (moderate certainty).
1 finding from 1 review
Tumour response · people with advanced gastric cancer
Combination leads to higher tumour response compared with single‐agent chemotherapy (high certainty).
1 finding from 1 review
Time to progression · people with advanced gastric cancer
Combination probably leads to lower time to progression compared with single‐agent chemotherapy (moderate certainty).
1 finding from 1 review
Treatment‐related death · people with advanced gastric cancer
Combination showed no clear difference in treatment‐related death compared with single‐agent chemotherapy (moderate certainty).
1 finding from 1 review
IBS symptoms · people with IBS
1 finding from 1 review
Treatment success as defined by the authors · people with inflammatory bowel disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Abdominal pain frequency or change in frequency · people with inflammatory bowel disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found